<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03802526</url>
  </required_header>
  <id_info>
    <org_study_id>NVP-1805_DDI</org_study_id>
    <nct_id>NCT03802526</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1805-R1 and NVP-1805-R2</brief_title>
  <official_title>Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1805-R1 and NVP-1805-R2 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navipharm Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Navipharm Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the pharmacokinetics and safety/tolerability between
      NVP-1805-R1 and NVP-1805-R2
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      pharmacokinetics and safety/tolerability between NVP-1805-R1 and NVP-1805-R2
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 3, 2019</start_date>
  <completion_date type="Actual">September 27, 2019</completion_date>
  <primary_completion_date type="Actual">July 4, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic interaction</measure>
    <time_frame>0hours - 48hours</time_frame>
    <description>Area under the curve (AUC)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>NVP-1805-R1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: NVP-1805-R1
1 tablet, oral dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVP-1805-R2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: NVP-1805-R2
1 tablet, oral dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NVP-1805-R1 and NVP-1805-R2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: NVP-1801-R1 1 tablet and NVP-1801-R2 1 tablet co-administration(oral dosing)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-1805-R1</intervention_name>
    <description>1 tablet, multiple oral dosing</description>
    <arm_group_label>NVP-1805-R1</arm_group_label>
    <other_name>NVP-1805-R1(M)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-1805-R2</intervention_name>
    <description>1 tablet, multiple oral dosing</description>
    <arm_group_label>NVP-1805-R2</arm_group_label>
    <other_name>NVP-1805-R2(C)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NVP-1805-R1 and NVP-1805-R2</intervention_name>
    <description>NVP-1805-R1,1 tablet and NVP-1805-R2, 1 tablet, co-administration, multiple oral dosing</description>
    <arm_group_label>NVP-1805-R1 and NVP-1805-R2</arm_group_label>
    <other_name>NVP-1805-R1(M) and NVP-1805-R2(C)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female adults aged 19-45 years.

          -  BMI of &gt;18.5 kg/㎡ and &lt;27.0 kg/㎡ subject, weight more than 50kg.

          -  Voluntarily provided a witten consent to participate in this clinical study.

        Exclusion Criteria:

          -  Treatment with an investigational product (Phase I study or Biological study) within
             3month preceeding the first dose of study medication.

          -  History of (or presence) study medication absortion, distribution, metabolism(e.g.,
             liver/ductal, kidney, cardio-vascular, endocrine, respiratory, GI, hematology,
             oncology, CNS, musculo-skeletal) or related past medical/surgery history

          -  Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Sung Shin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gachon University Gil Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Navipharm</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi-do</state>
        <zip>16209</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>January 10, 2019</study_first_submitted>
  <study_first_submitted_qc>January 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2019</study_first_posted>
  <last_update_submitted>November 26, 2019</last_update_submitted>
  <last_update_submitted_qc>November 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

